NYU Langone Health
In age of misinformation, cancer care community seeks new ways to improve communication
An important component of cancer care is communication with patients and caregivers about their disease.
Venovenous ECMO for severe COVID-19 led to ‘exceptional early survival’ that was sustained
Patients with severe COVID-19 who received venovenous extracorporeal membrane oxygenation support had “exceptional early survival” to discharge that was sustained 1 year after cannulation, researchers reported in Annals of Thoracic Surgery.
Nasal exhalation of e-cigarette, hookah aerosols may raise lung inflammation, cancer risk
Many e-cigarette and hookah smokers exhale aerosols through the nose, which may increase risk for lung inflammation and nose, sinus and throat cancers, according to findings published in Tobacco Use Insights.
Patient-reported outcome measure thresholds differed by TSA type, diagnosis
TAMPA, Fla. — Researchers who identified differences in clinically relevant results for anatomic and reverse shoulder arthroplasty said understanding these prosthesis- and diagnosis-based differences can aid clinical decision-making.
Removing race-specific coefficient in eGFR equation impacts CKD trial inclusion
Removing the race-specific coefficient from the equation that determines eGFR results in a “small but potentially important” effect on the inclusion of patients in [chronic kidney disease] trials, according to published data.
ACTIV-4A
P2Y12 inhibitor plus anti-coagulation vs. anticoagulation alone in noncritically ill patients with COVID-19.
VIDEO: New understanding about fixation of posterior malleolus and syndesmosis fractures
WAIKOLOA, Hawaii — In this video from Orthopedics Today Hawaii, Toni M. McLaurin, MD, spoke about fractures of the posterior malleolus and syndesmosis.
Convalescent plasma may have benefited patients in early days of COVID-19 pandemic
Results from the CONTAIN COVID-19 trial showed that convalescent plasma did not meet prespecified efficacy endpoints in patients hospitalized with COVID-19.
Addition of P2Y12 inhibitor fails to benefit noncritically ill patients with COVID-19
In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation did not extend survival or lessen disease severity, according to results of the ACTIV-4a trial.
Study identifies predictors of worsening of atherogenic lipid profile during pandemic
Women and racial and ethnic minority groups were more likely to have substantial worsening of atherogenic lipid profiles during COVID-19 stay-at-home orders compared with before the pandemic, researchers reported.